The brochure provides you with an overview of the key features and benefits of our next-generation TrueDiscovery™ platform. In addition, it elaborates on our deep and reproducible proteome, phospho- and immune-proteome quantification and analysis. Finally, it digs into how we identify the most promising and actionable biomarkers for research and clinical decision-making.
The brochure provides you with an overview of the key features and benefits of our next-generation TrueSignature™ platform. In addition, it elaborates on the specificities of our customizable panels for clinical and pharmacodynamics studies.
In this white paper, you can learn about the key reasons why oncology drug development fails and how Biognosys’ proteomics platforms and applications can support your oncology research pipeline by:
• Understanding the right biology
• Hitting the right target
• Developing the right biomarkers
We describe a first-of-its-kind study using multi-omics biomarker approaches to demonstrate pharmacodynamic effects and immune modulation in pancreatic cancer. Biognosys’ proprietary platform for unbiased proteomics, TrueDiscovery™, allowed the identification of pharmacodynamic markers and elucidated the mechanism of action of therapies under clinical investigation.
The case study provides you with an overview of the key features and benefits of our next-generation Plasma Biomarker Discovery solution. In addition, the case study elaborates on the results from our latest pan-cancer proteomics study.
The case study provides you with an overview of the key features and benefits of our next-generation Immunopeptidome Profiling solution. In addition, the case study elaborates on the results of our latest immunopeptidomics study on lung cancer.
Cappelletti V, Hauser T, Piazza I, Pepelnjak M, Malinovska L, Fuhrer T, Li Y, Dörig C, Boersema P, Gillet L, Grossbach J, Dugourd A, Saez-Rodriguez J, Beyer A, Zamboni N, Caflisch A, Souza N, Picotti P. Cell
In this study, an ETH Zurich team led by Biognosys’ scientific advisor and inventor of the LiP-MS technology, Paola Picotti, has spearheaded the exploration of protein functional states in a proteome-wide manner. The team investigated the role of protein structural alterations as a first-line cellular response. Integrating peptide-level LiP-MS data with orthogonal information such as phosphorylation enabled the linking of protein structural changes to functional implications. This work demonstrates the potential of integrating structural and abundance-based proteomics to achieve deeper insights into biological processes.
Marco Tognetti, Kamil Sklodowski, Sebastian Müller, Dominique Kamber, Jan Muntel, Roland Bruderer and Lukas Reiter.
The plasma proteome has the potential to enable a holistic analysis of the health state of an individual. However, plasma biomarker discovery is difficult due to its high dynamic range and variability. Here, we present a novel automated analytical approach for deep plasma profiling and apply it to a 180-sample cohort of human plasma from lung, breast, colorectal, pancreatic, and prostate cancer.
J. Adam Hendricks, Nigel Beaton*, Alexey Chernobrovkin, Eric Miele, Ghaith M. Hamza, Piero Ricchiuto, Ronald C. Tomlinson, Tomas Friman, Cassandra Borenstain, Bernard Barlaam, Sudhir Hande, Michelle L. Lamb, Chris De Savi, Rick Davies, Martin Main, Joakim Hellner, Kristina Beeler, Yuehan Feng, Roland Bruderer, Lukas Reiter, Daniel Martinez Molina*, and M. Paola Castaldi*. American Chemical Society’s Chemical Biology Journal.
The publication shows how orthogonal proteomics approaches can be applied to quantitatively profile the selectivity of a new compound. Biognosys’ proprietary Limited Proteolysis Mass Spectrometry (LiP-MS) technology was used to screen the entire proteome and identify potential targets via structural alterations. In addition to target identification, by exploiting the technology’s peptide-level resolution – a unique feature of the approach – we could also identify the putative binding site of the CDK inhibitor. In this way, LiP-MS enabled the target identification, binding affinity estimation, and binding site localization of the analyzed compound.